Neurotrope Target of Unusually High Options Trading (NASDAQ:NTRP)

Neurotrope Inc (NASDAQ:NTRP) saw some unusual options trading on Wednesday. Stock traders acquired 1,187 call options on the stock. This represents an increase of 1,442% compared to the average volume of 77 call options.

Separately, ValuEngine downgraded Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday, February 25th.

Shares of Neurotrope stock opened at $6.89 on Thursday. Neurotrope has a 52 week low of $3.33 and a 52 week high of $11.93.

Neurotrope (NASDAQ:NTRP) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.47) EPS for the quarter.

Institutional investors have recently made changes to their positions in the company. Eaton Vance Management purchased a new position in shares of Neurotrope in the 4th quarter valued at approximately $164,000. Raymond James & Associates purchased a new position in shares of Neurotrope in the 4th quarter valued at approximately $42,000. BlackRock Inc. increased its position in Neurotrope by 17.9% during the 1st quarter. BlackRock Inc. now owns 24,577 shares of the company’s stock valued at $134,000 after buying an additional 3,729 shares in the last quarter. MYDA Advisors LLC bought a new position in Neurotrope during the 1st quarter valued at approximately $690,000. Finally, Renaissance Technologies LLC increased its position in Neurotrope by 113.3% during the 1st quarter. Renaissance Technologies LLC now owns 159,447 shares of the company’s stock valued at $869,000 after buying an additional 84,700 shares in the last quarter. Institutional investors and hedge funds own 13.87% of the company’s stock.

WARNING: “Neurotrope Target of Unusually High Options Trading (NASDAQ:NTRP)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2019/06/13/neurotrope-target-of-unusually-high-options-trading-nasdaqntrp.html.

Neurotrope Company Profile

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.

Recommended Story: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply